Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients (INTERACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05036824|
Recruitment Status : Recruiting
First Posted : September 8, 2021
Last Update Posted : September 8, 2021
|Condition or disease||Intervention/treatment|
|Covid19 Hospitalization||Drug: tinzaparin|
A prothrombotic state, attributable to a cytokine storm induced by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) and leading to activation of the coagulation cascade, is a recognized feature of Coronavirus disease 2019 (COVID-19) infection. This can manifest in venous thromboembolism (VTE), arterial thrombosis events (ATE), and disseminated intravenous coagulation (DIC) and coagulopathy are reflective of more severe disease and adverse prognosis. A significant number of patients with COVID-19 require single or multiple organ support on the Intensive Care Unit (ICU), estimated to be between 12 and 17% of patients. with the reported mortality in these cohorts between 25 and 40%.
International guidelines recommend that hospitalized patients with COVID-19 should receive pharmacological prophylaxis against VTE, in the absence of contraindications. With respect to how VTE prophylaxis is achieved, Low Molecular Weight Heparins (LMWH), in addition to their well-known anticoagulant properties, appear to have additional antiviral and anti-inflammatory effects that may be potentially beneficial in hospitalized COVID-19 patients.
Though international and national guidelines state that all hospitalized patients with COVID-19 should receive pharmacologic thromboprophylaxis, the rising incidence of thrombotic complications in COVID-19 patients has led a lot of hospitals to adopt the strategy of increasing the dose of anticoagulation for prophylaxis to 'intermediate' or "therapeutic" doses using a risk-adapted strategy with increased doses administration based on factors associated with increased risk; clinicians weigh the benefits and risks of therapeutic anticoagulation in terms of thrombosis and major bleeding risk for individual patients.
Additionally, LMWHs have different physicochemical characteristics as a result of the diverse methods of their manufacturing. The variations in molecular composition and pharmacological properties of LMWHs are reflected in differences in their clinical efficacy and safety. Each LMWH should, therefore, be considered as a unique substance. Tinzaparin is the only LMWH known that is prepared by enzymatic hydrolysis with heparinase. Due to its preparation method, tinzaparin has distinct properties than other LMWHs including and not limited to: higher Anti-IIa activity and Anti-Xa/Anti-IIa activity ratio, the higher release of Tissue Factor Pathway Inhibitor (TFPI), less dependence from renal function for its clearance, and more complete neutralization from its antidote, if needed. Due to the key role of increased Thrombin generation (IIa) and Tissue factor (TF) pathway activation in COVID-19-associated thrombosis , special properties of tinzaparin in Anti-IIa activity and TFPI production and release from endothelial cells, as well as significant effects of TFPI in various vascular, inflammatory, cardiovascular, hematological and oncological disorders, tinzaparin could have an expanded role beyond its well-known anticoagulant function.
The purpose of this study is to evaluate the overall clinical effectiveness and safety of 'intermediate' or "therapeutic" doses of anticoagulation with tinzaparin administered for thromboprophylaxis in COVID-19 patients with moderate disease severity during hospitalization in Greek hospitals.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Intensive Dose Tinzaparin in Hospitalized COVID19 Patients|
|Estimated Study Start Date :||October 1, 2021|
|Estimated Primary Completion Date :||March 31, 2022|
|Estimated Study Completion Date :||April 30, 2022|
Patients admitted to hospital with COVID-19, PCR+ SARS-CoV-2 infection administered thromboprophylaxis with tinzaparin.
Dosage: intermediate or therapeutic dose Frequency of tinzaparin administration: once daily Duration: Unknown
Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
Other Name: Innohep
- Incidence of thrombotic events [ Time Frame: through study completion, an average of 6 months ]Evaluate the incidence of thrombotic events: total & per type e.g. PE, DVT, symptomatic, incidental, proximal, distant etc. (Measured as percentage of events in relation to the study population)
- Incidence of bleeding events [ Time Frame: through study completion, an average of 6 months ]Evaluate τηε ιncidence of bleeding events (total & per type e.g. Major, CRNMB and minor) (Measured as percentage of events in relation to the study population)
- WHO progression scale [ Time Frame: through study completion, an average of 6 months ]Evaluate the patients in relation to World Health Organization (WHO) progression scale (range from 0 (healthy) to 10 (death); values below or equal to 5 correspond to the absence of any oxygen supply beside nasal or facial mask).
- Length of hospital stay [ Time Frame: through study completion, an average of 6 months ]Evaluate the length of hospital stay (in days)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05036824
|Contact: Karolina Akinosoglou, MD,PhDfirstname.lastname@example.org|
|University Hospital of Patras||Recruiting|
|Patras, Achaia, Greece, 26504|
|Contact: Karolina Akinosoglou, Ass. Prof. +30 2610997254 email@example.com|
|Evangelismos General Hospital||Recruiting|
|Athens, Attica, Greece, 10676|
|Contact: George Marakomichelakis, M.D. Ph.D.|
|Sub-Investigator: Christine Vadala, M.D. Ph.D.|
|General Hopital Elpis||Recruiting|
|Athens, Attica, Greece, 11522|
|Contact: Spyridon Savvanis, M.D. Ph.D|
|University General Hospital of Ioannina||Recruiting|
|Ioannina, Epirus, Greece, 45500|
|Contact: Haralampos ] Milionis, Ass. Prof.|
|General Hospital of Kerkira "Ag. Irini"||Recruiting|
|Korfu, Ionian Islands, Greece, 49100|
|Contact: Ilias Papanicolaou, M.D. Ph.D.|
|General Hospital of Kozani "Mamatsio"||Recruiting|
|Kozáni, Macedonia, Greece, 50100|
|Contact: Efthalia Randou, M.D. Ph.D.|
|Genereal Hospital of Patras "Ag. Andreas"||Recruiting|
|Patras, Peloponnese, Greece, 26335|
|Contact: George Efremidis, M.D. Ph.D.|
|Principal Investigator:||Karolina Akinosoglou, MD,PhD||University Hospital of Patras|